Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma
<p dir="ltr">This report highlights the risk of latent tuberculosis (TB) reactivation after treatment with Polatuzumab Vedotin (PV), Rituximab, and Bendamustine (PBR protocol) despite appropriate chemoprophylaxis. A 48‐year‐old male with refractory Burkitt's lymphoma (BKL) was t...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513545607053312 |
|---|---|
| author | Sarah A. Elkourashy (21632903) |
| author2 | Maria Benkhadra (19756941) Laila Shafei (17045772) Sulieman Abujarir (21632906) Rola Ghasoub (16555851) |
| author2_role | author author author author |
| author_facet | Sarah A. Elkourashy (21632903) Maria Benkhadra (19756941) Laila Shafei (17045772) Sulieman Abujarir (21632906) Rola Ghasoub (16555851) |
| author_role | author |
| dc.creator.none.fl_str_mv | Sarah A. Elkourashy (21632903) Maria Benkhadra (19756941) Laila Shafei (17045772) Sulieman Abujarir (21632906) Rola Ghasoub (16555851) |
| dc.date.none.fl_str_mv | 2024-05-07T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/ccr3.8838 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Disseminated_tuberculosis_after_Polatuzumab_Vedotin_based_chemoimmunotherapy_in_a_patient_with_Burkitt_s_lymphoma/29445464 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences bendamustine Burkitt's lymphoma polatuzumab vedotin reactivation rituximab tuberculosis |
| dc.title.none.fl_str_mv | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">This report highlights the risk of latent tuberculosis (TB) reactivation after treatment with Polatuzumab Vedotin (PV), Rituximab, and Bendamustine (PBR protocol) despite appropriate chemoprophylaxis. A 48‐year‐old male with refractory Burkitt's lymphoma (BKL) was treated with PBR protocol. At baseline, the patient had a negative QuantiFERON test result, which turned out to be positive prior to starting PBR. He received chemoprophylaxis for 9 months and was compliant with treatment. One year later, he was admitted with COVID‐19 pneumonia and was treated according to the protocol. His symptoms persisted for 1 month. Investigations yielded disseminated TB‐infiltrated bone marrow and pleura. Downstream B‐cell and T‐cell depletion secondary to CD20 and CD79b antagonism may potentially explain the increased risk of TB reactivation associated with the combination of PV and rituximab. Further research is necessary to monitor the risk of TB reactivation among patients receiving a combination of PV and rituximab, especially in endemic areas with high prevalence and incidence of TB.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/ccr3.8838" target="_blank">https://dx.doi.org/10.1002/ccr3.8838</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_ac24e571c773d3a41f0e6fe6edca9757 |
| identifier_str_mv | 10.1002/ccr3.8838 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29445464 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphomaSarah A. Elkourashy (21632903)Maria Benkhadra (19756941)Laila Shafei (17045772)Sulieman Abujarir (21632906)Rola Ghasoub (16555851)Biomedical and clinical sciencesImmunologyOncology and carcinogenesisPharmacology and pharmaceutical sciencesbendamustineBurkitt's lymphomapolatuzumab vedotinreactivationrituximabtuberculosis<p dir="ltr">This report highlights the risk of latent tuberculosis (TB) reactivation after treatment with Polatuzumab Vedotin (PV), Rituximab, and Bendamustine (PBR protocol) despite appropriate chemoprophylaxis. A 48‐year‐old male with refractory Burkitt's lymphoma (BKL) was treated with PBR protocol. At baseline, the patient had a negative QuantiFERON test result, which turned out to be positive prior to starting PBR. He received chemoprophylaxis for 9 months and was compliant with treatment. One year later, he was admitted with COVID‐19 pneumonia and was treated according to the protocol. His symptoms persisted for 1 month. Investigations yielded disseminated TB‐infiltrated bone marrow and pleura. Downstream B‐cell and T‐cell depletion secondary to CD20 and CD79b antagonism may potentially explain the increased risk of TB reactivation associated with the combination of PV and rituximab. Further research is necessary to monitor the risk of TB reactivation among patients receiving a combination of PV and rituximab, especially in endemic areas with high prevalence and incidence of TB.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/ccr3.8838" target="_blank">https://dx.doi.org/10.1002/ccr3.8838</a></p>2024-05-07T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/ccr3.8838https://figshare.com/articles/journal_contribution/Disseminated_tuberculosis_after_Polatuzumab_Vedotin_based_chemoimmunotherapy_in_a_patient_with_Burkitt_s_lymphoma/29445464CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/294454642024-05-07T03:00:00Z |
| spellingShingle | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma Sarah A. Elkourashy (21632903) Biomedical and clinical sciences Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences bendamustine Burkitt's lymphoma polatuzumab vedotin reactivation rituximab tuberculosis |
| status_str | publishedVersion |
| title | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| title_full | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| title_fullStr | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| title_full_unstemmed | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| title_short | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| title_sort | Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma |
| topic | Biomedical and clinical sciences Immunology Oncology and carcinogenesis Pharmacology and pharmaceutical sciences bendamustine Burkitt's lymphoma polatuzumab vedotin reactivation rituximab tuberculosis |